List view / Grid view
Regulatory changes are reshaping toxicology, with precision now at the forefront. We explore how accurate target analysis is transforming drug development, particularly for biotherapeutics.
The global small molecule drug discovery market is set for significant growth. Explore the key factors driving this expansion, from rising R&D investments to the increasing role of AI and CROs.
Metrion Biosciences is set to accelerate its global expansion and enhance its leadership in ion channel drug discovery services.
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
The era of precision medicine demands more rigorous biomarker validation methods. While ELISA has long been the gold standard, advanced technologies such as LC-MS/MS and Meso Scale Discovery (MSD) offer superior precision, sensitivity and efficiency. Here, Prasad Lakshmanan Selvaraj, Director of Technical Review at Sannova, explains that by embracing these…
2 August 2024 | By Eurofins Discovery
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.
Researchers screened over 2,000 small molecules and have now more than doubled the known compounds reported to induce trained immunity.
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
A novel screening tool may increase the five-year survival rate of hepatocellular carcinoma patients to 90 percent.
The AI model screened the medical records of heart failure patients more accurately, quickly and cheaply, compared to study staff.
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
This report provides exclusive access to content on innovative screening methods to improve detection and diagnosis of prevalent conditions like cancer and metabolic disease, with expert insights from leading professionals in the field.
The screening model combines maternal history, ultrasound data and several tests for blood markers to enable personalised treatment.
Patients with no detectable FLT3 mutations had the best outcomes after an allogenic hematopoietic cell transplant.
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
